• This is a political forum that is non-biased/non-partisan and treats every person's position on topics equally. This debate forum is not aligned to any political party. In today's politics, many ideas are split between and even within all the political parties. Often we find ourselves agreeing on one platform but some topics break our mold. We are here to discuss them in a civil political debate. If this is your first visit to our political forums, be sure to check out the RULES. Registering for debate politics is necessary before posting. Register today to participate - it's free!

Eli Lilly says antibody drug ‘may reduce hospitalisations’ for Covid-19

JacksinPA

Supporting Member
DP Veteran
Monthly Donator
Joined
Dec 3, 2017
Messages
26,290
Reaction score
16,771
Gender
Male
Political Leaning
Progressive
Eli Lilly says antibody drug ‘may reduce hospitalisations’ for Covid-19 | South China Morning Post

Interim trial data suggests the experimental treatment has ‘a direct antiviral effect’ on patients with mild and moderate symptoms, according to company

It’s designed to block the coronavirus from entering human cells, neutralise it and potentially treat the disease


US pharmaceutical firm Eli Lilly on Wednesday said its experimental drug for Covid-19 appeared to reduce the need for hospital treatment during a trial on patients with mild and moderate symptoms.

The drug maker tested three different doses of the monoclonal antibody treatment, LY-CoV555, against a placebo in a trial involving people who had recently been diagnosed with the disease.

Antibodies are proteins the body makes in response to invasion by a foreign substance such as a virus. The experimental drug is designed to work against the spike protein of Sars-CoV-2, the coronavirus that causes Covid-19, by blocking the virus from entering human cells, neutralising it and potentially preventing and treating the disease.
It was manufactured in a laboratory from a blood sample taken from one of the first US patients who recovered from Covid-19.

For the trial, which began in June, 452 people were recruited who had been recently diagnosed with Covid-19 but were not seriously ill or in hospital. Five of the 302 patients who were given the drug were later admitted to hospital, while nine of the 150 placebo patients ended up in hospital

That suggested a 72 per cent reduction in the risk of being admitted to hospital for patients given the antibody drug compared to those given the placebo, Eli Lilly said.
“These interim data suggest that LY-CoV555 has a direct antiviral effect and may reduce Covid-related hospitalisations,” Daniel Skovronsky, Eli Lilly’s chief scientific officer and president of Lilly Research Laboratories, said in a statement. “The results reinforce our conviction that neutralising antibodies can help in the fight against Covid-19.”
Global coronavirus tally nears 30 million as rich nations snap up vaccine stocks

The drug maker said most of the patients, including those given the placebo, had shown almost complete viral clearance by day 11 of the trial. Only those on the middle dose of the antibody drug, 2,800mg, achieved the goal of significantly reducing the viral load in patients’ blood after 11 days.

The lower dose group on 700mg and the higher dose on 7,000mg did not meet this target.

No drug-related serious adverse events were reported during the trial, and similar adverse events were seen across all dose groups that were comparable to the placebo, the company said.
================================================
Sounds like a very positive development. Not a vaccine but an anti-viral drug.
 
Monoclonal antibodies like this one are usually administered by infusion (an IV drip). They are also expensive.
 
Good news indeed if this can be easily administered. A combination of vaccine and treatments not requiring hospitalization are a great step toward getting back to some semblance of normal.
 
Good news indeed if this can be easily administered. A combination of vaccine and treatments not requiring hospitalization are a great step toward getting back to some semblance of normal.

I agree.

Targeting the S or spike protein of the virus is not a sure bet for a successful monoclonal antibody. The business end of the S protein is covered to an extent with carbohydrate molecules called glucan. This covers a lot of the amino acids in the protein, making them not accessible to the antibody. I don't know how much variation there is in the placement of the glucan but the monoclonal antibody to be effective has to recognize one specific amino acid on the surface of the S protein. If there is some variation in the placement of the glucan due to a mutation & you develop the monoclonal antibody from the wrong amino acid, it would limit its effectiveness. It would bind to only some of the viruses.
 
Last edited:
Back
Top Bottom